Focus: Rocket Pharmaceuticals is a public-stage gene therapy company focused on neurological and rare genetic disorders, headquartered in New York with a lean operational footprint.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
6 added, 4 removed. Backfill posture.
2 recent layoff filings (12 mo) — 160 affected
Source: state DOL filings via Big Local News
Rocket is a bet-the-company gene therapy play with clinical diversity but pre-revenue cash burn trajectory; best for scientists seeking frontier research exposure willing to accept equity volatility and uncertain timelines.
Help build intelligence for Rocket Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rocket Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
No public FDA or regulatory red flags, but pre-revenue cash burn and declining cash reserves present material solvency risk within 18-24 months without licensing deal or capital raise.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo